vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.2倍（$185.1M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 33.3%，领先1.3%），Doximity, Inc.同比增速更快（9.8% vs 7.6%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 24.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
CPRX vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.2倍
$152.6M
营收增速更快
DOCS
高出2.1%
7.6%
净利率更高
CPRX
高出1.3%
33.3%
两年增速更快
DOCS
近两年复合增速
24.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $185.1M |
| 净利润 | $52.7M | $61.6M |
| 毛利率 | 82.9% | 89.9% |
| 营业利润率 | 40.5% | 38.9% |
| 净利率 | 34.5% | 33.3% |
| 营收同比 | 7.6% | 9.8% |
| 净利润同比 | -5.8% | -18.1% |
| 每股收益（稀释后） | $0.40 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXDOCS
| Q4 25 | $152.6M | $185.1M | ||
| Q3 25 | $148.4M | $168.5M | ||
| Q2 25 | $146.6M | $145.9M | ||
| Q1 25 | $141.4M | $138.3M | ||
| Q4 24 | $141.8M | $168.6M | ||
| Q3 24 | $128.7M | $136.8M | ||
| Q2 24 | $122.7M | $126.7M | ||
| Q1 24 | $98.5M | $118.1M |
净利润CPRXDOCS
| Q4 25 | $52.7M | $61.6M | ||
| Q3 25 | $52.8M | $62.1M | ||
| Q2 25 | $52.1M | $53.3M | ||
| Q1 25 | $56.7M | $62.5M | ||
| Q4 24 | $55.9M | $75.2M | ||
| Q3 24 | $43.9M | $44.2M | ||
| Q2 24 | $40.8M | $41.4M | ||
| Q1 24 | $23.3M | $40.6M |
毛利率CPRXDOCS
| Q4 25 | 82.9% | 89.9% | ||
| Q3 25 | 84.7% | 90.3% | ||
| Q2 25 | 85.9% | 89.2% | ||
| Q1 25 | 87.3% | 89.5% | ||
| Q4 24 | 84.7% | 91.6% | ||
| Q3 24 | 85.0% | 90.0% | ||
| Q2 24 | 87.4% | 89.3% | ||
| Q1 24 | 87.3% | 89.4% |
营业利润率CPRXDOCS
| Q4 25 | 40.5% | 38.9% | ||
| Q3 25 | 44.7% | 37.8% | ||
| Q2 25 | 45.2% | 37.4% | ||
| Q1 25 | 44.8% | 35.2% | ||
| Q4 24 | 44.3% | 47.4% | ||
| Q3 24 | 39.6% | 38.8% | ||
| Q2 24 | 44.2% | 36.4% | ||
| Q1 24 | 27.5% | 35.5% |
净利率CPRXDOCS
| Q4 25 | 34.5% | 33.3% | ||
| Q3 25 | 35.6% | 36.8% | ||
| Q2 25 | 35.6% | 36.5% | ||
| Q1 25 | 40.1% | 45.2% | ||
| Q4 24 | 39.4% | 44.6% | ||
| Q3 24 | 34.1% | 32.3% | ||
| Q2 24 | 33.2% | 32.7% | ||
| Q1 24 | 23.6% | 34.4% |
每股收益（稀释后）CPRXDOCS
| Q4 25 | $0.40 | $0.31 | ||
| Q3 25 | $0.42 | $0.31 | ||
| Q2 25 | $0.41 | $0.27 | ||
| Q1 25 | $0.45 | $0.31 | ||
| Q4 24 | $0.44 | $0.37 | ||
| Q3 24 | $0.35 | $0.22 | ||
| Q2 24 | $0.33 | $0.21 | ||
| Q1 24 | $0.19 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $979.3M |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXDOCS
| Q4 25 | $709.2M | $64.8M | ||
| Q3 25 | $689.9M | $169.2M | ||
| Q2 25 | $652.8M | $137.3M | ||
| Q1 25 | $580.7M | $209.6M | ||
| Q4 24 | $517.6M | $165.3M | ||
| Q3 24 | $442.3M | $184.2M | ||
| Q2 24 | $375.7M | $111.4M | ||
| Q1 24 | $310.4M | $96.8M |
股东权益CPRXDOCS
| Q4 25 | $954.3M | $979.3M | ||
| Q3 25 | $920.2M | $1.1B | ||
| Q2 25 | $856.0M | $1.0B | ||
| Q1 25 | $794.3M | $1.1B | ||
| Q4 24 | $727.6M | $1.0B | ||
| Q3 24 | $660.9M | $961.2M | ||
| Q2 24 | $608.7M | $913.6M | ||
| Q1 24 | $561.4M | $901.4M |
总资产CPRXDOCS
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $971.9M | $1.2B | ||
| Q1 25 | $908.9M | $1.3B | ||
| Q4 24 | $851.4M | $1.2B | ||
| Q3 24 | $772.0M | $1.1B | ||
| Q2 24 | $706.4M | $1.1B | ||
| Q1 24 | $646.7M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $60.9M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXDOCS
| Q4 25 | $44.9M | $60.9M | ||
| Q3 25 | $32.4M | $93.9M | ||
| Q2 25 | $71.3M | $62.1M | ||
| Q1 25 | $60.0M | $98.5M | ||
| Q4 24 | $70.9M | $65.2M | ||
| Q3 24 | $72.9M | $68.3M | ||
| Q2 24 | $64.1M | $41.2M | ||
| Q1 24 | $31.9M | $63.9M |
自由现金流CPRXDOCS
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
自由现金流率CPRXDOCS
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度CPRXDOCS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.1% | 0.0% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
现金转化率CPRXDOCS
| Q4 25 | 0.85× | 0.99× | ||
| Q3 25 | 0.61× | 1.51× | ||
| Q2 25 | 1.37× | 1.16× | ||
| Q1 25 | 1.06× | 1.58× | ||
| Q4 24 | 1.27× | 0.87× | ||
| Q3 24 | 1.66× | 1.55× | ||
| Q2 24 | 1.57× | 1.00× | ||
| Q1 24 | 1.37× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
